Skip to main content
Equibles

Anthony Pagano

CFO

Genmab A/S (GMAB)

Equibles does not estimate personal net worth.

Get an email with a short summary when Genmab A/S publishes a filing, an earnings call transcript or a press release.

Get GMAB alerts

About Anthony Pagano

Anthony Pagano is recorded as CFO at Genmab A/S (GMAB). Anthony Pagano has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for Genmab A/S on August 6, 2026. Genmab A/S is classified in the Biotechnology industry within the Healthcare sector.

Anthony Pagano on recent calls

“The first half of of 2026 demonstrated the continued strength of our business with revenue growing 25% year over year. Beyond the headline 25% revenue growth, I'd highlight two characteristics of our performance.”
CFO, Earnings conference call (announced in 6-K) ·
“Before diving into the numbers, as we highlighted last quarter, please note that these results and guidance in our remarks exclude the impact of acquisition-related expenses, including amortization.”
CFO, Earnings conference call (announced in 6-K) ·
“2026 is really set up to be a very important year for GEMMAB and our lay stage pipeline. And really, it's about the collection of the three brands, Epkinly, Rina S, and Pitocentimab.”
CFO, Barclays 28th Annual Global Healthcare Conference ·
“2025 was a year of strong execution for GenMAP. With solid revenue growth, expanding profitability, and disciplined investment. Looking ahead, our 2026 guidance reflects the same framework we outlined at Q3 and at the time of the Meris acquisition.”
CFO, Genmab A/S Q4 FY2025 Earnings Call ·
“We have achieved solid revenue growth over the first nine months of 2025, driven by ongoing recurring revenues and strong market performance of our products.”
CFO, Genmab A/S Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Recent activity

Show 14 earlier activities